CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?-MedSci.cn

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

Xu, BH; Fan, Y

Xu, BH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China.

LANCET ONCOLOGY, 2021; 22 (2): 159

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

科室

工具

服务